Antiseizure medication in patients with meningioma: a retrospective cohort study on the long-term impact on depression, anxiety and neurocognitive functioning - Summary - MDSpire
Advertisement
Antiseizure medication in patients with meningioma: a retrospective cohort study on the long-term impact on depression, anxiety and neurocognitive functioning
To evaluate the long-term influence of antiseizure medication (ASM) use, particularly levetiracetam, on depression, anxiety, and neurocognitive functioning in patients with meningioma.
Key Findings:
Over one third of meningioma patients experience epileptic seizures, which can impact mood and cognition.
Levetiracetam is the most commonly used ASM, with potential cognitive benefits that may influence treatment choices.
Limited evidence exists on the impact of ASM on mood and cognition specifically in meningioma patients, highlighting a need for further research.
Interpretation:
The study aims to clarify the relationship between ASM use and neuropsychiatric outcomes in meningioma patients, addressing a significant gap in existing literature regarding long-term effects.
Limitations:
Retrospective design may introduce bias, potentially affecting the reliability of the findings.
Limited generalizability due to specific patient selection criteria, which may not represent the broader meningioma population.
Potential confounding factors not fully controlled, which could influence the observed outcomes.
Conclusion:
This study seeks to provide insights into the long-term effects of ASM on mood and cognition in meningioma patients, which is crucial for informed treatment decisions and improving patient care.
by L. Laribi, J. C. C. Scheepens, A. H. Zamanipoor Najafabadi, M. J. Vos, W. R. van Furth, S. M. Peerdeman, M. J. B. Taphoorn, P. B. Van der Meer, J. A. F. Koekkoek
